IL1R1 and cryopyrin-associated periodic syndrome: Therapeutic suppression of the unwanted inflammatory responses in CAPS patients can be achieved by IL‐1R blockade with the IL‐1 receptor antagonist anakinra, or canakinumab, a monoclonal antibody targeting IL‐1R1 34, 35.